Drug Trial Radar · NCT04418219
Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer
Last checked: Nov 20, 2026Latest source record: Apr 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Dec 21, 2020
Primary completion
Jan 1, 2023
Study completion Jan 1, 2024
Sponsor
- Lead sponsor
- Thomas Jefferson UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 5, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I/II trial studies the side effects of a breast cancer vaccine (SV-BR-1-GM) and how well it works in combination with pembrolizumab for the treatment of breast cancer that is persistent, has come back (recurrent), or has spread to other places in the body (metastatic). Breast cancer vaccine SV-BR-1-GM is a human breast cancer cell line that has been genetically engineered to produce a substance called "GM-CSF" (granulocyte-macrophage colony stimulating factor) which occurs naturally in the body. GM-CSF is normally produced by white blood cells and helps the body develop immunity to disease-causing germs. Immunotherapy with monoclonal antibodies such as pembrolizumab may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Anti-cancer drugs such as cyclophosphamide may help boost the immune response. Interferon alpha 2b may help stimulate the immune system to fight cancer. This trial may help doctors see whether SV-BR-1-GM injections help boost the immune system and/or help control or help shrink breast cancer along with the other drugs that also boost the immune system.
Conditions
- Anatomic Stage IV Breast Cancer AJCC v8
- Metastatic Breast Carcinoma
- Prognostic Stage IV Breast Cancer AJCC v8
- Recurrent Breast Carcinoma
- Refractory Breast Carcinoma
Interventions
CyclophosphamideDrug
alkylating agent used in the treatment of several forms of cancer including leukemias, lymphomas and breast cancer.
Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GMBiological
Breast Cancer Vaccine SV-BR-1-GM, Bria-IMT, GM-CSF Gene-transfected Breast Cancer Vaccine SV-BR-1-GM, SV-BR-1 Breast Cancer Cell Line Vaccine, SV-BR-1-GM, SV-BR-1-GM Vaccine
PembrolizumabBiological
1374853-91-4, Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S\>P))gamma 4 Heavy Chain (134-218'')-disulfide with Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'''':229-229'''')-bisdisulfide, Keytruda, Lambrolizumab, MK-3475, PEMBROLIZUMAB, SCH 900475
Recombinant Interferon Alpha 2b-like ProteinBiological
Novaferon, Recombinant IFN Alfa-2b-like Protein
Questionnaire AdministrationOther
Ancillary studies
Quality of Life AssessmentOther
Ancillary studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse eventsTime frame: up to 1 year
- Objective response rate (ORR)Time frame: up to 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.